ARTICLE | Tools & Techniques

Making mAbs en masse

January 14, 2010 8:00 AM UTC

A primary goal for antibody makers is capturing the full diversity of mAbs generated by the human immune system, then isolating and cloning individual memory cells that produce mAbs against a particular antigen. But harnessing the high diversity and efficacy of human mAbs for therapeutic application has proven difficult because of the challenges in identifying and then isolating the cells that produce them.

AIMM Therapeutics B.V. researchers have published the latest approach tackling this hurdle, but the jury is still out on which of a number of competing technologies will perform better. Ultimately the answer may depend on the specific application and indication for a given platform...